

Thursday 30 January 2025

09.30 - 10.15 **Registration and welcome with coffee/tea**

10.15 - 10.25 **Opening by the chair of the NVED**

10.25 - 11.30 **Session I - Human skin models for novel applications**

Session chairs: Ellen van den Bogaard (*Radboudumc*) and Jasper Koning (*AmsterdamUMC*)

1. Britt van der Leeden *AmsterdamUMC* Development and characterization of a reconstructed human skin burn wound model.
2. Joliene Wichers Schreur *LUMC* Development of human skin equivalents representing cutaneous T-cell lymphoma.
3. Luca Meesters *Radboudumc* iPSC-derived keratinocyte models for in vitro atopic dermatitis research.
4. Kim Schilders *ADBC* Generation of full skin constructs from hair follicle stem cells.
5. Jonas Jäger *AmsterdamUMC* Towards next generation reconstructed human skin: monocyte perfusion of a vascularized dermis in a multi-organ-chip.

11.30 - 12.10 Guest lecture by **dr. Raymond Staals** (*WUR*): **“CRISPR-Cas, from a bacterial defense system to a powerful genetic tool in humans”**

12.10 - 13:10 **Lunch**

13.10 - 14.15 **Session II - Immunology**

Session chairs: Ferenc Scheeren (*LUMC*) and Rosalie Luiten (*AmsterdamUMC*)

6. Fenna de Bie *LUMC* Flow cytometry of skin biopsies in CTCL patients during Mogamulizumab treatment.
7. Ahmed Elfiky *UMCU* Impact of dupilumab and upadacitinib treatment on epigenetic and transcriptomic alterations in skin-homing T cells of atopic dermatitis patients.
8. Emma Holtappels *AmsterdamUMC* Identifying biological processes involved in clinical response to treatment in the autoimmune disease vitiligo using proteomics.
9. Nicoline van Buchem *AmsterdamUMC* The potential role of trained immunity in the pathogenesis of autoimmune vitiligo.
10. Alex Rooker *AmsterdamUMC* Vitiligo-associated bystander lysis in basal cell carcinoma.

14.15 - 15.45 **Poster presentations session I with coffee and tea; *selection for poster walks by jury***

14:15 - 15:00 → *odd poster numbers presenting at poster*

15:00 - 15:45 → *even poster numbers presenting at poster*

- P1. Juliette Kersten (*LUMC*) Modified recommendations for the radiation dose in patients with cutaneous T-cell lymphoma and localised lesional disease: a retrospective analysis of treatment outcomes.
- P2. Malak Al-Gawahiri (*Radboudumc*) The importance of psychological and socioeconomic risk factors for depression and anxiety among Dutch patients with mild-to-severe psoriasis: a web-based survey study.
- P3. Digna de Bruin (*CHDR*) Imaging and immune-response profiling after UV-B provocation in healthy volunteers for proof-of-mechanism clinical trials.
- P4. Rosanne Ottevanger (*LUMC*) Exploring the association of primary cutaneous CD30+ lymphoproliferative disorders and Inflammatory Bowel Disease in a Dutch cohort.
- P5. Lisa van der Rijst (*UMCU*) Treatment goals and preferences of pediatric atopic dermatitis patients, young adults, and caregivers.
- P6. Lisa van der Rijst (*UMCU*) Dupilumab-associated ocular surface disease in pediatric atopic dermatitis patients: results from the BioDay registry.
- P7. H. Ibrahim Korkmaz (*AmsterdamUMC*) The post-burn immune response in burn patients: a pivotal role for complement.
- P8. Leon Miltner (*UMCG*) Multimorbidity in adults with atopic dermatitis in a population-based cohort.
- P9. Liana Barenbrug (*Radboudumc*) Incorporating the patients' voice in healthcare practice and information provision regarding family planning and pregnancy: a questionnaire study among Dutch patients with psoriasis.
- P10. Florentine de Boer (*AmsterdamUMC*) Effect of repeated low dose UVR exposure on the skin inflammation threshold, skin biomarkers and vitamin D in healthy adults.
- P11. Andrew Morrison (*AmsterdamUMC*) Lymphatic endothelial cells enhance the physiology of a perfused vascularised lymph node-on-chip for studying skin-immune responses.
- P12. Noor van Hout (*Radboudumc*) Engineered live biotherapeutic products and their effects on UV light-irradiated keratinocytes.
- P13. Linda Godding (*Radboudumc*) Searching for relevant biomarkers in dermatological care: a survey among Dutch patients and dermatological care providers.
- P14. Juliette Simons (*UMCU*) Diagnostic management and monitoring of cholinergic urticaria patients in daily practice.
- P15. Shidi Wu (*LUMC*) Tumor-stroma interaction facilitates cutaneous T Cell Lymphoma cell proliferation and dynamic phenotype change in cancer-associated fibroblasts.
- P16. Lian van der Gang (*UMCU*) Early efficacy of dupilumab in atopic dermatitis: patient-reported outcomes *versus* objective sleep and scratching measures.
- P17. Lian van der Gang (*UMCU*) Daily practice experience of dupilumab treatment in patients with prurigo nodularis: a 28-week evaluation of clinical effectiveness and safety from the BioDay registry.
- P18. Nienke Veldhuis (*UMCU*) Ocular surface disease in pediatric patients with moderate-to-severe atopic dermatitis.
- P19. Thijs van der Mark (*GGD Amsterdam*) Development and validation of blunt trauma in a reconstructed human skin model.
- P20. Reineke Soegiharto (*UMCU*) Side effects of omalizumab in patients with chronic urticaria: a long-term multi-centre real-world study.
- P21. Reineke Soegiharto (*UMCU*) Exploring the disease duration of urticaria and associated clinical characteristics in Dutch primary care.
- P22. Nikita Koster (*CHDR*) A prospective, multi-center, observational biomarker real-world evidence study for in-depth profiling of patients with chronic immune-mediated inflammatory skin diseases in daily practice.
- P23. Rindert Venema (*UMCG*) Isolation and generation of a monoclonal human anti-desmoglein 3 antibody.
- P24. Margot Starrenburg (*ErasmusMC*) Dupilumab treatment decreases MBC2s, correlating with reduced Ige levels in pediatric atopic dermatitis.
- P25. Marjolein Brands (*UMCG*) The validity and reliability of patient-provided photographs for the diagnosis and severity of hand eczema – preliminary results.

- P26. Roland Valentin Bumbuc (*AmsterdamUMC*) The acute phase response to burn injury: an in-silico modeling approach.
- P27. Tristan Bruijn (*NKI*) A systematic review of changes in melanocytic naevi during immune checkpoint inhibition and targeted therapy.
- P28. Birte Hell (*UMCU*) In vitro skin models for sensitization in food allergy.
- P29. Emily Kallen (*UMCU*) Almond allergy in adults: low discriminative ability for both almond sIgE and SPT.
- P30. Fauve van Veen (*MUMC+*) Exploring experiences and considerations in reproductive decision-making for patients with genodermatoses: a qualitative interview study.
- P31. Jaimy Klijnhout (*Radboudumc*) *Staphylococcus aureus* strain-specific host defense responses in keratinocytes.
- P32. Fauve van den Berge (*ErasmusMC*) SKINERGY CINDU: An exploratory multi-centre, two-part study to deep-phenotype chronic inducible urticaria and explore biomarkers for omalizumab response using a multimodal profiling approach.
- P33. Mengyao Zhou (*VU Amsterdam*) Polarization second harmonic generation imaging of collagen fiber organization in human healthy and scarred skin.
- P34. Nikki Henckens (*Radboudumc*) Patients' and clinicians' perspectives on telemedicine to monitor patients on systemic treatment for psoriasis or atopic dermatitis - a mixed methods study.
- P35. Marie Chevalier (*LUMC*) Tumour micro-environment in chlormethine responders and non-responders in an early-stage mycosis fungoides cohort, using imaging mass cytometry.
- P36. Marjolein Hiel (*UMCG*) Navigating the challenges in clinical trials for bullous pemphigoid and pemphigus: learnings from the clinical trial graveyard and an international expert survey.
- P37. Zixian Liang (*UMCG*) Diagnostic value of complement fixation test in routine diagnostics of pemphigoid diseases: one year of prospective analysis.
- P38. Cisse Vermeer (*UMCG*) Safety of antisense oligonucleotide therapy: A systematic review and meta-analysis on adverse events in clinical studies.
- P39. Fieke Rosenberg (*UMCG*) A genome-wide association study of contact allergy to p-phenylenediamine.

15.45 – 16.50 Session III - Biomarkers and genetics

Session chairs: Dirk-Jan Hijnen (*Radboudumc*) and Antoni Gostynski (*MUMC+*)

- | | |
|--------------------------------------|--|
| 11. Alesha Louis <i>LUMC</i> | The human skin microbiome and physical barrier integrity in aging. |
| 12. Sara Marchisio <i>LUMC</i> | Evaluation of CD39, CD73, and CD38 as potential biomarkers for monitoring Mogamulizumab response in Sézary Syndrome. |
| 13. Eddy de Boer <i>UMCG</i> | Long-read sequencing cracks unsolved cases in Epidermolysis Bullosa. |
| 14. Merve Hatun ErKayman <i>UMCG</i> | IgA is related to a more severe mucous membrane pemphigoid. |
| 15. Marie-Eline Debeuf <i>MUMC+</i> | Exploring the therapeutic effect of Er:YAG laser on Hailey-Hailey disease through transcriptomics. |

16:55 - 17:25 Marcel Jonkman lecture by **dr. Marieke Bolling** (*UMCG*): **“Opportunities and challenges in the past and future in the field of genodermatoses”**

17.30 - 19.45 **Drinks and Dinner**

19.45 - 20.30 **25th general assembly of the NVED**

20.30 - 01.00 **PubQuiz and Dancing**

Friday 31 January 2025

09.00 - 10.05 Session IV – Treatment of atopic dermatitis

Session chairs: Martijn van Doorn (*ErasmusMC*) and Robert Rissmann (*CHDR*)

16. Lisa van der Rijst *UMCU* Impact of dupilumab on immune-related proteins in skin tape strips and serum of pediatric atopic dermatitis patients.
17. Florence Vroman *UMCU* The effect of dupilumab on the microbiome of lesional skin, facial skin and nose in moderate to severe AD patients treated in daily practice: data from the BioDay registry.
18. Aranka Gerritsen *Radboudumc* Restoring interleukin(IL)-22 induced severe atopic dermatitis (AD) hallmarks in vitro by dual targeting of epidermal defects and inflammation.
19. Margot Starrenburg *UMCU* Impact of tralokinumab on skin-homing T cells and IL-4 and IL-13 receptor dynamics in patients with atopic dermatitis.
20. Nienke Veldhuis *UMCU* Long-term ophthalmological follow-up of atopic dermatitis patients treated with dupilumab.

10.05 - 11.10 Poster presentations (selected for poster prize) with coffee and tea

11.10 - 12.15 Session V – Innovations in dermato-oncology

Session chairs: Remco van Doorn (*LUMC*) and Marcel Bekken (*AmsterdamUMC*)

21. Wouter Ouwerkerk *AmsterdamUMC* Cancer-immunogram analyses to predict the heterogeneous clinical response to immunotherapy in metastatic melanoma patients.
22. Myrthe Moermans *MUMC+* Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in treatment of Bowen's disease: long-term results of a multicenter randomized controlled trial.
23. Elise Beljaards *LUMC* Association of skin barrier function, bacterial colonization, and inflammation with disease activity in mycosis fungoides and Sézary syndrome.
24. Veerle Merkus *LUMC* Tumor microenvironment of metastasized and non-metastasized cutaneous squamous cell carcinoma in organ transplant patients.
25. Inger Kreuger *LUMC* Spatial gene expression and micro-environmental changes during nevus to melanoma transition.

12.15 - 13.15 Lunch

13.15 - 13.55 Guest Lecture by **Prof. dr. Barbara Horvath** (*UMCG*): “**Autoimmune blistering diseases; Bridging basic research and clinical outcomes**”

13.55 - 15.00 Session VI – Inflammatory skin disease and biologics

Session chairs: Marjolein De Bruin-Weller (*UMCU*) and Heike Röckmann (*UMCU*)

26. Catherine Mergen *LACDR* Stratum corneum ceramide alterations and barrier dysfunction in psoriasis normalize with guselkumab treatment.
27. Linda Godding *Radboudumc* Real-world cost-per-responder among the different classes of biologics for psoriasis.

28. Reineke Soegiharto *UMCU* The distinct serum protein profile of chronic spontaneous urticaria compared to healthy controls and atopic dermatitis.
29. Marjolein Hiel *UMCG* Phenotype transition in relapsed pemphigus patients after rituximab therapy: a retrospective single-center analysis.
30. Juliette Simons *UMCU* Effectiveness of ciclosporin in omalizumab-refractory chronic urticaria patients.

15.00 - 15.15 Awards for best presentation and poster

15.15 Closure

Meeting Location:

Congress hotel 'De Werelt'
Westhofflaan 2
6741 KH Lunteren
Tel: 0318-484641

Accreditation:

The NVDV has awarded 11 points for full participation in this scientific meeting last year; accreditation for 2025 is applied for.

Program committee:

Michel van Geel (*MUMC+*), Ellen van den Bogaard (*Radboudumc*), Gilles Diercks (*UMCG*), Luba Pardo (*ErasmusMC*), Walbert Bakker (*AmsterdamUMC*), Abdoel El-Ghalbzouri (*LUMC*), Daphne Bakker (*UMCU*), Ibrahim Korkmaz (*AmsterdamUMC*)

Jury for presentation prize:

Hanna Niehues (*Radboudumc*), Joost Meyer (*UMCG*), Tom Wolswijk (*MUMC+*)

Jury for poster prize:

Emma Holtappels (*AmsterdamUMC*), Gilles Diercks (*UMCG*), Ferenc Scheeren (*LUMC*)

NVED board:

Remco van Doorn (president and representative in NVDV 'Commissie Nascholing', *LUMC*), Antoni Gostynski (*MUMC+*), Rosalie Luiten (secretary, *AmsterdamUMC*), Jeroen Bremer (treasurer, *UMCG*), Patrick Zeeuwen (coordination abstracts and program, *Radboudumc*)